Bluejay Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://bluejaytx.com
Clinical Trials
6
Active:0
Completed:1
Trial Phases
3 Phases
Phase 1:4
Phase 2:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (66.7%)Not Applicable
1 (16.7%)Phase 2
1 (16.7%)A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
Not Applicable
Recruiting
- Conditions
- Chronic Hepatitis D Infection
- Interventions
- Drug: Brelovitug 300 mgDrug: Bulevirtide 2 mg and Brelovitug - 300 mg
- First Posted Date
- 2025-10-01
- Last Posted Date
- 2025-11-17
- Lead Sponsor
- Bluejay Therapeutics, Inc.
- Target Recruit Count
- 172
- Registration Number
- NCT07200908
- Locations
- 🇨🇿
Institute For Clinical And Experimental Medicine, Prague, Prague, Czechia
🇨🇿Klin Med s.r.o., Prague, Prague, Czechia
🇩🇪Goethe University Frankfurt, Frankfurt, Frankfurt, Germany
A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
Phase 2
Recruiting
- Conditions
- Chronic Hepatitis D Infection
- Interventions
- Drug: Brelovitug 300 mgDrug: Brelovitug 900 mgDrug: Delayed Treatment with Brelovitug 300mg
- First Posted Date
- 2025-04-02
- Last Posted Date
- 2025-11-17
- Lead Sponsor
- Bluejay Therapeutics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06907290
- Locations
- 🇨🇦
233 Calgary, Calgary, Calgary, Canada
🇨🇦235 Montreal, Montreal, Quebec, Canada
🇮🇱212 Haifa, Haifa, Haifa District, Israel
News
No news found